Givastomig

Description

Givastomig ABL111, TJ033721 is a bispecific antibody BsAb inhibitor. Givastomig can specifically binds to Claudin18.2 CLDN 18.2 on the surface of cancer cells and 4-1BB CD137, TNFRSF9 on the surface of activated T cells and natural killer NK cells. Givastomig is engineered to contain a single Fc-domain mutation asparagine to alanine to eliminate Fc-effector function. Givastomig-bound cell lines expressing a range of CLDN18.2 levels with high affinity and induced 4-1BB activation only in the context of CLDN18.2 binding. Givastomig can be used for the study of colon carcinoma.